Cystic Fibrosis

Join Clinical Trials for Cystic Fibrosis

Join Clinical Trials for Cystic Fibrosis

General Purpose: Individuals who develop cystic fibrosis do so because they have inherited two faulty genes, one from each parent. As such, cystic fibrosis is caused solely by genetic mutations and is most common among Caucasians of northern European ancestry.

However, it is also common among Latinos as well as certain groups of American Indians. Because the underlying cause of cystic fibrosis is known, much research continues to focus on the role that genes play in the development of the lung disease associated with cystic fibrosis.

In addition, there is considerable research investigating new and improved treatment options for lung infections in children with cystic fibrosis, as well as studies that are seeking to determine how new medicines and other therapies can help to improve the quality of life for people with this burdensome condition.

Continued … Cystic Fibrosis Clinical Trials (Click to Open)

Join Clinical Trials for Cystic Fibrosis

Cystic Fibrosis Clinical Trials

What Will Clinical Trials for Cystic Fibrosis Be Like?

When participating in Clinical Trials for Cystic Fibrosis, a few common tests and procedures may be involved; however, the ultimate design of the particular study will determine which specific procedures you will undergo.

Many studies will involve the use of blood tests to screen for genetic characteristics.  A chest x-ray may also be used to view the heart, lungs, and blood vessels in order to observe inflammation, scarring, and air-trapping. In addition, some studies may involve the use of a sinus x-ray in order to determine the presence of sinusitis, which is a common complication of cystic fibrosis.

Additional tests and procedures that may also be involved in cystic fibrosis research include: lung function tests; sputum/spit cultures; prenatal screening (for pregnant women); and simple blood testing to determine if non-symptomatic individuals are carriers for the genetic mutations that cause cystic fibrosis. Genetic counseling may also be involved in some clinical trials.

Typical Cystic Fibrosis Clinical Trial Protocol:

Research related to cystic fibrosis covers a wide range of topics. Specific examples might Cystic Fibrosis Clinical Trialsinclude the following types of studies:

  • A study designed to investigate how genetic mutations actually lead to the symptoms of cystic fibrosis.
  • A study designed to investigate newly-developed respiratory therapies, antibiotics, anti-viral medications, and other treatments for lung infections in children with cystic fibrosis.
  • A study designed to investigate the association between smoking status and genetic mutations that lead to the development of cystic fibrosis.
  • Studies evaluating the feasibility and effectiveness of various types of exercise on the symptoms associated with cystic fibrosis.
  • A study designed to evaluate how existing treatments and newly-developed treatments compare in their ability to improve the quality of life among patients with cystic fibrosis.

Suggested Search Terms:

“cystic fibrosis exacerbation,” “cystic fibrosis therapy,” “cystic fibrosis gene therapy,” “cystic fibrosis children,” “cystic fibrosis exercise,” and “cystic fibrosis smoking.” 

Current Search Term:

“Cystic Fibrosis”



Pregnancies and Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   Hospices Civils de Lyon
Active, not recruiting


Clearance of 25-hydroxyvitamin D in Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:   Drug: d6-25-hydroxyvitamin D3
Sponsors:   University of Washington;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting


A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects


Condition:   Cystic Fibrosis
Interventions:   Drug: FDL169;   Drug: Placebo
Sponsor:   Flatley Discovery Lab LLC
Recruiting


Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis


Condition:   Cystic Fibrosis
Interventions:   Drug: Tobi Inhalant Product;   Drug: Nebcin
Sponsor:   University Hospital, Lille
Recruiting


The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis


Condition:   Cystic Fibrosis
Interventions:   Drug: Oral Glutathione;   Drug: Placebo
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Cystic Fibrosis Foundation Therapeutics
Recruiting


Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:   Other: cardiopulmonary exercise testing
Sponsor:   University Hospital, Lille
Recruiting


Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)


Condition:   Cystic Fibrosis
Interventions:   Drug: GLPG1837 dose 1;   Drug: GLPG1837 dose 2;   Drug: GLPG1837 dose 3
Sponsor:   Galapagos NV
Completed


Integrating Supportive Care in Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:   Behavioral: Supportive Care Intervention
Sponsors:   University of Pittsburgh;   Cystic Fibrosis Foundation Therapeutics
Recruiting


Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis


Condition:   Pulmonary Cystic Fibrosis
Interventions:   Other: Placebo;   Drug: QBW276
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting


Puberty in Girls Followed for Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:   Procedure: Data collection
Sponsor:   University Hospital, Toulouse
Completed


Electrical Impedance Imaging of Patients With Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:   Device: CT scan
Sponsors:   Colorado State University;   Children's Hospital Colorado;   University of Colorado, Denver
Enrolling by invitation


Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)


Condition:   Cystic Fibrosis
Intervention:   Drug: ivacaftor
Sponsor:   Vertex Pharmaceuticals Incorporated
Active, not recruiting


Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis


Condition:   Cystic Fibrosis
Interventions:   Device: High-Flow, 20 LPM (via Optiflow cannula);   Device: Low FLow, 5 LPM (via Optiflow cannula)
Sponsor:   Virginia Commonwealth University
Recruiting


Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation


Condition:   Cystic Fibrosis
Intervention:   Drug: Ivacaftor
Sponsors:   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation Therapeutics
Completed


Extrapulmonary Effects of Cystic Fibrosis on Physical Activity of Adult Patients.


Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed


Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients


Condition:   Cystic Fibrosis
Interventions:   Drug: IgY;   Drug: Placebo
Sponsor:   Mukoviszidose Institut gGmbH
Completed


Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis


Condition:   Cystic Fibrosis
Interventions:   Drug: Inhaled Reduced Glutathione;   Drug: Physiological solution
Sponsors:   Serafino A. Marsico;   Federico II University
Unknown status


Costimulatory Molecules as Biomarkers in Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   Oregon Health and Science University
Completed


28 Day Repeat Dose in Cystic Fibrosis Patients


Condition:   Cystic Fibrosis
Interventions:   Drug: SB656933;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed


RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum


Condition:   Cystic Fibrosis
Intervention:   Drug: Pulmozyme
Sponsor:   University Hospital, Tours
Completed


Infant Study of Inhaled Saline in Cystic Fibrosis


Condition:   Cystic Fibrosis
Interventions:   Drug: 7% Hypertonic Saline (HS);   Drug: 0.9% Isotonic Saline (IS)
Sponsors:   CF Therapeutics Development Network Coordinating Center;   Cystic Fibrosis Foundation Therapeutics;   National Heart, Lung, and Blood Institute (NHLBI)
Completed


Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:   Drug: inhaled 7% hypertonic saline (HS)
Sponsors:   CF Therapeutics Development Network Coordinating Center;   Cystic Fibrosis Foundation Therapeutics
Completed


Absorptive Clearance in the Cystic Fibrosis Airway


Condition:   Cystic Fibrosis
Intervention:   Other: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Sponsor:   University of Pittsburgh
Completed


Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis


Condition:   Cystic Fibrosis
Intervention:   Drug: Biaxin ( clarithromycin)
Sponsors:   Wake Forest University;   Abbott
Completed


Studying Patients With Cystic Fibrosis and Other Pulmonary and Pancreatic Disorders


Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Refine Your Search Advanced Search